AIM
SRNE

Alambic Investment Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Alambic Investment Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-417,034
Closed -$2.15M – 478
2018
Q1 		$2.15M Buy
417,034
+377,182
+946% +$2.68M 0.3% 122
2017
Q4 		$151K Buy
+39,852
New +$104K 0.02% 424

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alambic Investment Management's SRNE Position: Q2 2018 in Review

Alambic Investment Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2018, closing a stake of 417,034 shares — an estimated $2.15M sold.

Alambic Investment Management first reported a position in SRNE in Q4 2017 and held it in 2 quarters. The position peaked at $2.15M in Q1 2018. 94 funds tracked by Wall St. Rank hold SRNE as of Q2 2018.

  • Alambic Investment Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Alambic Investment Management sold 417,034 Sorrento Therapeutics, Inc. shares in Q2 2018, an estimated $2.15M.
  • Alambic Investment Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2017 and held it in 2 quarters.
  • Alambic Investment Management's Sorrento Therapeutics, Inc. position peaked at $2.15M in Q1 2018.
  • 94 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2018.

Based on Alambic Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.